FDA Declines to Approve Capricor Duchenne Treatment Over Unreliable Trial Data
The FDA declined to approve Capricor's Duchenne treatment, citing unreliable trial data. Capricor shares slumped.
The FDA declined to approve Capricor's Duchenne treatment, citing unreliable trial data. Capricor shares slumped.